Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Abstract

Background: Transient elastography (TE) is a new modality for the diagnosis of liver fibrosis caused by various etiologies. This study was conducted to determine the accuracy of TE in detecting the different stages of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients.

Methods: MEDLINE/PubMed, Embase, Ovid, Cochrane Library, American College of Physicians (ACP) Journal Club, Google Scholar, Database of Abstracts of Reviews of Effects, and Web of Science that evaluated the liver stiffness by means of TE and liver biopsy were enrolled in this systematic review and meta-analysis. Published articles were extracted from 2002 to March 2015.

Results: A total of 7 articles from 114 papers were included which consisted of 698 patients. The results indicated that when F ≥3, the outcomes were 93.7% (95% confidence interval (CI): 92-95.5), 91.1% (95% CI: 89-93.2), 82.4% (95% CI: 79.9-84.9), and 95.9% (95% CI: 94.4-97.4) for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), respectively. With fibrosis stage ≥4, it has reached the sensitivity of 96.2 % (95% CI: 94.5-97.8), a specificity of 92.2% (95% CI: 89.9-94.6), a PPV of 5.5% (95% CI: 51.2-59.8) and NPV of 98.5% (95% CI: 97.4-99.5).

Conclusion: We concluded that as the pathological fibrosis increases, the sensitivity, specificity and NPV of TE in the diagnosis of fibrosis improves in NAFLD patients. TE can be considered as a unique alternative instead of liver biopsy in NAFLD patients and it has an important role in the exclusion of liver cirrhosis. More studies are required to confirm the results.

Keywords: Transient elastography, Fibro scan, Fibrosis, Non-alcoholic fatty liver disease

Citation: Hashemi SA, Alavian SM, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Intern Med 2016; 7(4): 242-252.

Non-alcoholic fatty liver disease has been considered as one of the main etiology of chronic liver disease globally (1, 2). Non-alcoholic fatty liver disease (NAFLD) has two main subgroups including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NASH has been defined as steatosis with inflammation, hepatocellular injury and possible fibrosis. Sometimes the final outcomes of NASH are cirrhosis and hepatocellular carcinoma. NAFL and NASH are different spectrum of the same histological disease (3, 4). The gold standard tool to diagnose NAFLD is liver biopsy and histological study and various stages are clarified according to histopathological investigations (3). There are some limitations for liver biopsy like invasive nature, complications, low level of individuals' satisfaction and sampling variation (5).
Pain and hypotension are major complications of liver biopsy and can lead to increased length of hospital stay and cost (6). The mortality rate after percutaneous liver biopsy has been reported as 1 in 10000 to 1 in 12000 (7). Therefore performing continuous liver biopsy for follow-up is practically impossible (8).

There were many investigations which tried to find methods to identify NASH including imaging evaluations and blood tests but still these procedures could not diagnose it well (9). Consequently, investigators are trying to find non-invasive valuable procedure in the diagnosis of liver stiffness/fibrosis. In this regard, application of Fibroscan (transient elastometer) (Echo Sens, Paris, France) is a device that can examine liver stiffness (10, 11). Diagnosis of liver stiffness and fibrosis by this method was reported previously (12, 13). Thus serial evaluation of liver stiffness can provide evidence about the progression of liver diseases like NASH (14). Transient elastography (TE or FibroScan ® - FS) was first described in France (15, 16), then in other parts of the world (17-22).

Lately published studies have shown that TE is valuable in detecting fibrosis and cirrhosis in chronic hepatitis patients (23-25) but with some limitations in overweight patients (26, 27). Nonetheless, the role of TE has not been well established in NAFLD/NASH patients due to non-optimal function of TE in overweight and obese people which is prevalent in people with NAFLD. Therefore, the aim of the current investigation was to assess the accuracy of TE in detecting various stages of fibrosis in NAFLD patients.

**Methods**

**Literature Search and quality assessment:** Systematic review of the literature published in English about transient elastography for the diagnosis and staging of NAFLD/NASH was performed with the help of the following: MEDLINE/PubMed, Embase, Ovid, Cochrane Library, and American College of Physicians (ACP) Journal Club, Google Scholar, Database of Abstracts of Reviews of Effects, and Web of Science. We evaluated the sources between 2002 (when TE was first introduced) to March 2015. The search terms used were (FibroScan, transient elastography, elastography and liver, liver stiffness, noninvasive method and liver stiffness, liver fibrosis, NASH, NAFLD, fatty liver, steatosis, assessment, staging). Only full length papers were enrolled for primary assessment and case reports, review articles, meta-analysis and systematic review papers and letter to editors were removed. For quality, we used the quality assessment of diagnostic accuracy studies (QUADAS) checklist (28). Each paper meeting the inclusion criteria was analyzed by 2 independent reviewers (Seyed Moayed Alavian and Seyyed Abbas Hashemi). Two independent reviewers (Seyed Moayed Alavian and Seyyed Abbas Hashemi) studied all candidate papers, and they retrieved the full texts of published articles that could not be evaluated with the title and abstract alone. Articles which reported information needed for the meta-analysis were included in this study. We included 7 full papers in which liver biopsy was listed as the reference for the assessment of TE for fibrosis in NAFLD patients.

**Study Inclusion criteria:** Articles were selected according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (29). The inclusion criteria for the articles included: 1) investigations that only examined the NAFLD/NASH patients, 2) evaluated the performance of TE to establish liver fibrosis stages, 3) used reliable liver staging system, 4) examined the diagnostic value of TE and expressed sensitivity, specificity, positive predictive values (PPVs), or negative predictive values (NPVs) for the diagnosis of fibrosis stage based on certain cutoff TE values, 5) studies with at least 30 subjects to provide enough evidence to approve the outcomes (figure 1).

![Figure 1. Flow sheet of the included databases.](image-url)
Study exclusion criteria: Our exclusion criteria were the following: 1) if the article did not include the patients with NAFLD/NASH, 2) did not use a fibrosis staging system, 3) did not report sensitivity, specificity, PPVs, or NPVs, 4) articles that were not in English, 5) only the abstract form existed, 6) review or other types of paper which were not in the opinion of investigators (research studies which investigated NAFLD in hepatitis B virus (HBV), hepatitis C virus (HCV) patients and other etiologies.

Data extraction: The authors extracted the required information from articles independently. The following data were age, sex, and body mass index (BMI), number of cases, the area under the receiver operating characteristic curve (AUROC); the median liver stiffness; liver biopsy size and stage: sensitivity, specificity, PPV and NPV. We used “blinding” “separation task” method to decrease bias.

Statistical analysis and meta-analysis: The mean value and standard deviation were calculated for numerical variables with normal distribution. Qualitative variables were indicated as numbers and percentages. 95% confidence intervals were calculated for each predictive test and a p-value < 0.01 was considered as significant for each statistic test. Sensitivity analysis was done to evaluate variations and there were no variations in pooling effect. Demographic features of the current studies were indicated in table 1. Nobili et al. (34) showed that liver stiffness (LS) detected by TE more than 9 kPa was associated with high stage of fibrosis in pathology (table 2). Yoneda et al. (35) evaluated LS in 97 NAFLD patients. There were significant correlation between METAVIR (36) score and different stages (p<0.0001) (table 2). Based on the METAVIR scoring system, fibrosis is staged on a scale from F0 to F4, including: F0: no fibrosis; F1: portal fibrosis, without septa; F2: few septa; F3: many septa without cirrhosis; and F4: cirrhosis, respectively.

Table 1. Main patients’ characteristics of the research populations in the studies that were enrolled in this paper; BMI (body mass index): Numerical variables with normal distribution were indicated as mean value ± standard deviation, while variables with non-normal distribution were reported as median values and range intervals

| Study                  | Year | Patient | Male        | Female       | Age           | BMI            |
|------------------------|------|---------|-------------|--------------|---------------|----------------|
| Lupșor et al. (37)     | 2010 | 72      | 51 (70.8%)  | 21 (29.2%)   | 42 (20-69)    | 28.71 (20.96-41.53) |
| Wong et al. (French cohort) (8) | 2010 | 128     | 74 (57.8%)  | 54 (42.1%)   | 53±13         | 29.1±5.1        |
| Wong et al. (Chinese cohort) (8) | 2010 | 118     | 61 (51.7%)  | 57 (48.3%)   | 49 ±9         | 26.9±3.4        |
| Bold et al. (38)       | 2012 | 30      | -           | -            | -             | -              |
| Yoneda et al. (35)     | 2008 | 97      | 40          | 57           | 51.8±13.7     | 26.6±4.2       |
| Nobili rt al. (34)     | 2008 | 50      | -           | -            | -             | 13.6±2.4       |
| Gaia et al. (39)       | 2011 | 72      | 52          | 20           | 48 (24 -65)   | 27.5 (21.1-40.4) |
| Mahadeva et al. (40)   | 2013 | 131     | 69 (52.7%)  | 62 (47.3%)   | 49.9 ± 12.3   |                |
Table 2. Concordance between fibrosis stages according to liver biopsy and TE in different investigations; Transient elastography (TE), fibrosis (F), Area under the Receiver Operating Characteristic Curve (AUROC), LB: Liver Biopsy, LS: Liver Stiffness, non-alcoholic steatohepatitis (NASH).

| Study                        | Diagnosis Of NASH | Scoring system | Liver Stiffness (kPa) | Liver Biopsy: Length (mm)/Portal Tracts (n) | Stage (n) | AUROC Value | Liver Stiffness (kPa) Median | Liver Stiffness (kPa) Cutoff Value |
|------------------------------|-------------------|----------------|----------------------|---------------------------------------------|-----------|-------------|-----------------------------|-----------------------------------|
| Lupsor et al. (37)          | liver biopsy      | Brunt          | 2.80 to              | 11 (6-20 mm/11 (7-22) portal spaces         | F0: 25 (34.7%) F1: 29 (40.3%) F2: 13 (18.1%) F3: 5 (6.9%) | F≥2: 1: 0.879 | F0: 4.90 (2.80-7.30) F1: 6.15 (4.80-12.50) F2: 6.90 (3.30-16.90) F3: 14.00 (10.70-14.10) | F≥2: 1.5  F≥3: 2.6  F≥4: 10.4 |
| Wong et al. (French cohort)  | liver biopsy      | Kleiner        | 9.7 ±9.7             | 24 ±8 mm/-                                    | F0:11.4 F1:42 F2:36 F3:21 F4:15 | F2≥2: 0.87 | F0: 5.7 ±1.8 F1: 6.8 ± 2.4 F2: 7.8 ±2.4 F3:11.8 ±5.2 F4:25.1 ±17.1 | F≥2: 7.0  F≥3: 8.7  F≥4: 10.3 |
| Wong et al. (Chinese cohort)| liver biopsy      | Kleiner        | 8.6 ±6.4             | 18±3 mm/-                                     | F0:56.5 F1:33 F2:9 F3:10 F4:10 | F2≥2: 0.84 | F0: 5.7 ±1.8 F1: 6.8 ± 2.4 F2: 7.8 ±2.4 F3:11.8 ±5.2 F4:25.1 ±17.1 | F≥2: 7.0  F≥3: 8.7  F≥4: 10.3 |
| Bokl et al (38)              | liver biopsy      | Kleiner        | 2.40 to              | 10 mm/-                                      | F0: 18 F1: 6 F2: 4 F3: 2 | Stage≥1: 0.78 Stage≥2:0.78 Stage≥3:1.0 | F0: 4.76 ±1.58 Stage:25.35 Stage:25.35 Stage:25.35 | F≥2: 1.5 3.5 4.3 5.35 |
| Yoneda et al. (35)           | liver biopsy      | Brunt          | -                    | 20 mm/-                                      | F0: 18 (18.6%) F1: 28 (28.9%) F2: 24 (24.7%) F3: 18 (18.6%) F4: 9 (9.3%) | F2≥2: 0.86 | F0: 4.850 ± 0.893 F1: 7.382 ± 2.432 F2: 9.283 ± 3.492 F3:13.333 ± 4.712 F4:25.344 ± 6.058 | F≥2: 5.9  F≥3: 6.6  F≥4: 9.8  F≥4: 17.5  F≥4: 25.344 ± 6.058 |
| Nobili et al. (34)           | liver biopsy      | Brunt          | -                    | -                                            | F2≥2: 0.99 F3: 1.0 F≥4: 10 | F0: 5.3 (3.0–9.7) F1: 6.15 (3.2–12.1) F2: 7.75 (4.3–13.9) F3: 9.4 ± 7.4 F4: 6.5 (4.3–10.3) | F≥2: 7.4  F≥3: 10.2  F≥4: 14.5  F≥4: 20.5  F≥4: 29.1 ± 27.2 |
| Gaia et al. (39)             | liver biopsy      | Brunt          | 6.6 (3.0–44.3)       | 25.2 mm (20–30.2)/-                          | F0: 23 (31.9) F1: 16 (22.2) F2: 16 (22.2) F3: 8 (11.1) F4: 9 (12.5) | F2≥2: 0.758 | F0: 5.3 (3.0–9.7) F1: 6.15 (3.2–12.1) F2: 7.75 (4.3–13.9) F3: 9.4 ± 7.4 F4: 6.5 (4.3–10.3) | F0: 21.23 vs F0: 23.45  F0: 23.45 vs F0: 23.45  F0: 23.45 vs F0: 23.45  F0: 23.45 vs F0: 23.45  F0: 23.45 vs F0: 23.45 |
| MAHADEVA et al. (40)         | liver biopsy      | Kleiner        | 9.0 ± 9.1            | 13.0 (8.0–15.0)/-                            | F0: 5 (3.8) F1: 51 (39.0) F2: 46 (35.1) F3: 21 (16.0) F4: 8 (6.1) | ≥F2≥F2: 0.67 ≥F3: 0.77 | F0: 5.7 ± 1.4 F1: 6.9 ± 2.3 F2: 8.7 ± 3.5 F3: 9.4 ± 7.4 F4: 10.60 | ≥F2: 6.65  ≥F3: 6.95  F0: 21.23 vs F0: 23.45  F0: 23.45 vs F0: 23.45  F0: 23.45 vs F0: 23.45 |
In this regard, a study (37) indicated the median LSM values according to the fibrosis stages were: 4.90 kPa for F0; 6.15 kPa for F1; 6.90 kPa for F2 and 14.00 kPa for F3, with significant difference between stages (table 2). Bokl et al. (38) revealed that as the stage of fibrosis increases, the accuracy of TE improves.

A study by Silvia Gaia et al. (39) examined 72 NAFLD patients using Brunt scoring system. They revealed liver stiffness (kPa). Cutoff value F0 vs F1234 was 5.5, F01 vs F234 became 7, F012 vs F4 was 8,F0123 vs F4 was 10.5 (table 2). An investigation (40) revealed that the accuracy of TE in describing the stage of fibrosis for ≥F3 was 0.77 (sensitivity 70.4% and specificity 66.6%) and for F4 was 0.95(sensitivity 87.5% and specificity 89.3%). Wong et al. (8) reported the role of TE in two ethnic groups including the Chinese and French population. They used Kleiner (41) ranking system. The results of French and Chinese population showed liver stiffness (kPa) cutoff values were F≥2: 7.0, F≥3: 8.7, F=4: 10.3 and F≥2: 7.0, F≥3: 8.7, F=4: 10.3, respectively (table 2). PPV, NPV, sensitivity, specificity with optimal cutoff and AUROC of all studies were summarized in table 3.

|                | Gaia (n:72) | Yoneda (N 97) | Bokl (N 30) | Nobili (N 50) | Lupstor (N 72) | Wong (N 246) | Mahadeva (N 131) |
|----------------|-------------|---------------|-------------|--------------|---------------|--------------|------------------|
| F≥ 1           |             |               |             |              |               |              |                  |
| AUROC          | 0.776       | 0.92          | 0.78        | -            | -             | -            |                  |
| Optimal cut-off (kPa) | 5.5         | 5.9           | 5.35        | -            | -             | -            |                  |
| Sensitivity (%) | 84          | 86            | 83          | -            | -             | -            |                  |
| Specificity (%) | 57          | 88            | 72          | -            | -             | -            |                  |
| PPV (%)        | 80          | 97            | 67          | -            | -             | -            |                  |
| NPV (%)        | 62          | 59            | 87          | -            | -             | -            |                  |
| F≥ 2           |             |               |             |              |               |              |                  |
| AUROC          | 0.8        | 0.86          | 0.78        | 0.99         | 0.78          | 0.84         |                  |
| Optimal cut-off (kPa) | 7          | 6.6          | 5.35        | 7.4          | 6.8           | 7.0          |                  |
| Sensitivity (%) | 76          | 88           | 83          | 100          | 66.6          | 79           |                  |
| Specificity (%) | 80          | 74           | 58          | 92           | 84.3          | 76           |                  |
| PPV (%)        | 75          | 79            | 33          | 80           | 60            | 70           |                  |
| NPV (%)        | 78          | 85            | 93          | 100          | 87            | 84           |                  |
| F≥ 3           |             |               |             |              |               |              |                  |
| AUROC          | 0.7        | 0.90          | 1.00        | 1.0          | 0.978         | 0.93         | 0.77             |
| Optimal cut-off (kPa) | 8          | 9.8          | 12.85       | 10.2         | 10.4          | 8.7          | 7.10             |
| Sensitivity (%) | 65          | 85           | 100         | 100          | 100           | 84           | 70.4             |
| Specificity (%) | 80          | 81           | 100         | 100          | 97            | 83           | 66.6             |
| PPV (%)        | 48          | 64            | 100         | 100          | 71            | 59           | 38.0             |
| NPV (%)        | 86          | 93            | 100         | 100          | 100           | 95           | 88.7             |
| F≥ 4           |             |               |             |              |               |              |                  |
| AUROC          | 0.94       | 0.99          | -           | -            | -             | 0.95         | 0.95             |
| Optimal cut-off (kPa) | 10.5       | 17.5         | -           | -            | -             | 10.3         | 11.30            |
| Sensitivity (%) | 78          | 100          | -           | -            | -             | 92           | 87.5             |
| Specificity (%) | 96          | 97           | -           | -            | -             | 88           | 89.3             |
| PPV (%)        | 70          | 75            | -           | -            | -             | 46           | 34.3             |
| NPV (%)        | 97          | 100           | -           | -            | -             | 99           | 99.1             |
In the current investigation, the analysis of primary outcomes using fixed or random-effects tests revealed that for patients with fibrosis stage of ≥1, sensitivity, specificity, PPV, NPV were equal to 83.7%, 78.2%, 92.2%, and 65.6%, respectively. In cases with fibrosis stage of ≥ 2, sensitivity was 87.5%, specificity was 78.4%, PPV was 69.9% and NPV was 89.5%. When liver fibrosis stage was ≥3, the calculated amounts were 93.7%, 91.1%, 82.4%, and 95.9% for sensitivity, specificity, PPV and NPV, respectively. When fibrosis stage was more than four (≥4) sensitivity reached to 96.2%, specificity was 92.2%, PPV 55.5% and NPV 98.5% (table 4). Fibrosis stage of F≥1 has two degrees of freedom. Results of meta-analysis for sensitivity, specificity, positive predictive value, negative predictive value were summarized in table 5. In fibrosis stage of F≥2, degrees of freedom was 5. Maximum I-squared index was noted for sensitivity of 91.8%. Results of meta-analysis for fibrosis stage of F≥2 were indicated in table 5. The highest statistical heterogeneity was calculated 229.5 for PPV and the lowest amount was 14.8 for NPV.

Table 4. Outcomes of meta-analysis; the results indicate the final accuracy of TE at different stages of fibrosis; for statistical analysis, the four stages of fibrosis according to Metavir and Brunt were considered equivalent. Confidence interval (CI), Positive Predictive Value (PPV), Negative Predictive Value (NPV), fibrosis (F)

| Biopsy stage | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) |
|--------------|------------------------|------------------------|----------------|----------------|
| F≥1          | 83.7% (78.6-88.7)       | 78.2% (72.8-83.6)      | 92.2% (88.7-95.7) | 65.6% (59.2-72.0) |
| F≥2          | 87.5% (85-90.1)         | 78.4% (75.2-81.7)      | 69.9% (66.3-73.5) | 89.5% (87.1-91.9) |
| F≥3          | 93.7% (92-95.5)         | 91.1% (89-93.2)        | 82.4% (79.9-84.9) | 95.9% (94.4-97.4) |
| F≥4          | 96.2% (94.5-97.8)       | 92.2% (89.9-94.6)      | 55.5% (51.2-59.8) | 98.5% (97.4-99.5) |

Table 5. Results of meta-analysis for sensitivity, specificity, positive predictive value, negative predictive value on various level of fibrosis; Positive Predictive Value (PPV), Negative Predictive Value (NPV), fibrosis (F)

| Heterogeneity statistic | Degrees of freedom | P value | I-squared | Tau-squared |
|-------------------------|--------------------|---------|-----------|-------------|
| F≥1, Sensitivity        | 2                  | 0.897   | 0.0%      | 0.000       |
| F≥1, Specificity        | 2                  | 0.000   | 91.0%     | 307.52      |
| F≥1,PPV                 | 2                  | 0.000   | 90.8%     | 191.84      |
| F≥1,NPV                 | 2                  | 0.001   | 85.6%     | 186.66      |
| F≥2, Sensitivity        | 5                  | 0.000   | 91.8%     | 128.68      |
| F≥2, Specificity        | 5                  | 0.001   | 76.0%     | 55.402      |
| F≥2,PPV                 | 5                  | 0.000   | 83.5%     | 114.18      |
| F≥2,NPV                 | 5                  | 0.000   | 85.0%     | 55.201      |
| F≥3, Sensitivity        | 6                  | 0.000   | 92.4%     | 82.26       |
| F≥3, Specificity        | 6                  | 0.000   | 89.7%     | 71.80       |
| F≥3,PPV                 | 6                  | 0.000   | 97.4%     | 514.27      |
| F≥3,NPV                 | 6                  | 0.020   | 59.4%     | 6.78        |
| F≥4, Sensitivity        | 3                  | 0.000   | 90.1%     | 42.59       |
| F≥4, Specificity        | 3                  | 0.004   | 77.8%     | 19.07       |
| F≥4,PPV                 | 3                  | 0.000   | 93.1%     | 302.15      |
| F≥4,NPV                 | 3                  | 0.815   | 0.0%      | 0.000       |

The highest I-squared index was observed in PPV (F≥3). Degrees of freedom was six (F≥3) (table 5). Figure 2 (frost plot) (a,b,c,d) showed sensitivity (figure 2 a), specificity (figure 2b), PPV(figure 2 c) and NPV (figure 2d) test when F≥3. When F≥4, statistical heterogeneity for sensitivity was 30.33, specificity was 13.49, for PPV was 43.75 and for NPV became 0.94. Degrees of freedom were calculated 3 for all statistical indexes when F≥4. I-squared index was 93.1%
and 90.1% for PPV and sensitivity, respectively (table 5). Figure 3 (frost plot) (a,b,c,d) revealed sensitivity (figure 3 a), specificity (figure 3 b), PPV (figure 3 c) and NPV (figure 3 d) when $F \geq 4$.
Discussion

In a meta-analysis study by Adebajo et al. (42), they examined the ultrasound-based TE for the diagnosis of hepatic fibrosis in recurrent hepatitis C virus after liver transplantation. Their finding showed that five papers examined fibrosis and indicated a sensitivity of 83% [95% confidence interval (CI): 77%-88%], and a specificity of 83% (95% CI: 77%-88%). Likewise with our results, in their practice the sensitivity and specificity of TE was high.

Chon et al. (43) performed a meta-analysis of 18 studies with 2772 chronic hepatitis B cases. They revealed that TE had high enough diagnostic accuracy for detecting liver fibrosis in patients with chronic hepatitis B. Similar to the present work, this article revealed the ability of TE in diagnosis of liver fibrosis although they did not evaluate the NAFLD patients. Chon et al. indicated that sensitivity and specificity for F2 were 74.3% and 78.3%, respectively. Predicting values for F3 were 74 and 63.8% and 84.6 and 81.5% for F4. Their results supported our findings from our research: as the fibrosis stage increased the accuracy of TE improved. In this regard, another meta-analysis reported by Talwalka et al. (44) showed that the sensitivity and specificity scores were 70 and 80.4 for F2, and 87 and 91 for F=4. Stebbing et al. (45) indicated the close amounts. In their study, chronic hepatitis C infection was the most common cause of fibrosis among the articles.

They revealed that the pooled estimates for significant fibrosis (≥F2) had a sensitivity of 71.9% [95% CI: 71.4%-72.4%] and specificity of 82.4% (95% CI: 81.9-82.9%). Tschoatzi et al. (46) revealed the sensitivity and specificity scores of 79 (95% CI 0.74–0.82) and 78(95% CI 0.72–0.83) for F≥2, and 83 and 89 for F=4. The current investigation indicated that patients with fibrosis stage of ≥2 had the sensitivity of 87.5%, and specificity of 78.4%. While stage F≥4 had the sensitivity of 96.2% and specificity of 92.2%. Our data showed more accuracy of TE in the diagnosis of fibrosis, but this difference could be due to etiology of fibrosis, which means that we only investigated the NAFLD patients while the reason of fibrosis in other papers was different.

Most of the mentioned papers discussed about the sensitivity and specificity of TE. In this particularity the present paper provided notable information about PPV and NPV of TE in detection of fibrosis. In a systematic review by J. K. Dowman et al. (47), they indicated that staging for NAFLD using a combination of radiology and laboratory procedures can decrease the requirement for invasive liver biopsy. Kwok R et al. revealed that the pooled sensitivities and specificities for TE to detect F ≥ 2, F ≥ 3 and F4 disease were 79% and 75%, 85% and 85%, 92% and 92% respectively. Like the current outcomes, they concluded that TE can exclude NAFLD patients with advanced fibrosis, primary evaluation is recommended to be done (48).

In Conclusion, TE has been validated in a wide spectrum of liver diseases like chronic hepatitis C (49-51), chronic hepatitis B (52-54), co-infection with human immunodeficiency virus (HIV) (55), alcoholic liver disease (56), primary biliary cirrhosis, and primary sclerosing cholangitis (57) and in the post-liver transplantation setting (58). These investigations indicated that TE was a valid method in the evaluation of fibrosis while liver biopsy was
taken as the gold reference standard. Most of these papers revealed that TE was accurate enough to detect high stage of fibrosis and cirrhosis without consideration of baseline etiology (59, 60). Our results proved that as the fibrosis stage increases, the accuracy of TE improves. As a result, considering TE in advanced fibrosis will have more real results close to liver histology. Furthermore, TE can indicate the progress of liver fibrosis and would be an accurate procedure in the follow-up of these patients.

The present study provided evidence that using TE in detecting level of fibrosis in NAFLD cases has high accuracy and can be a good alternative for liver biopsy in patients who cannot undergo invasive procedures. TE is an easy method to evaluate liver fibrosis, noninvasive, needing short time to obtain results appreciated by patients. Although further longitudinal investigations are needed to confirm the outcomes.

**Acknowledgments**

The authors are grateful to Bent-Al-Hoda Beyram for the secretarial assistance.

**Authors’ Contribution:** Study concept and design: Seyed Moayed Alavian, Acquisition of data: Seyed Moayed Alavian, Seyyed Abbas Hashemi, Mohammad Gholami Fesharaki, Analysis and interpretation of data: Seyed Moayed Alavian, Seyyed Abbas Hashemi, Mohammad Gholami Fesharaki, Drafting of the manuscript: Seyed Moayed Alavian, Seyyed Abbas Hashemi, Critical revision of the manuscript for important intellectual content: Seyed Moayed Alavian, Seyyed Abbas Hashemi, Statistical analysis: Mohammad Gholami Fesharaki, Administrative, technical, and material support: Seyed Moayed Alavian, Seyyed Abbas Hashemi, Study supervision: Seyed Moayed Alavian

**Funding:** This study was supported by Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran.

**Conflict of Interest:** There was no conflict of interest.

**References**

1. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-61.
2. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-98.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23
4. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-23.
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
6. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118: 96-8.
7. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400.
8. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
9. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
10. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49: 436-46.
11. Yeh WC, Li PC, Jeng YM, et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound in Med Biol 2002; 28: 467-74.
12. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
13. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
14. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29: 1705-13.
15. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
16. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography Fibroscan: a prospective study. Gut 2006; 55: 403-8.
17. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-45.
18. Lupşor M, Badea R, Ştefănescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008; 17: 155-63.
19. Kim KM, Choi WB, Park SH, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007; 42: 382-8.
20. Yoneda M, Fujita K, Inamori M, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330-1.
21. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008; 134: 8-14.
22. Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007; 37: 1002-10.
23. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and metaanalysis. Clin Gastroenterol Hepatol 2007; 5: 1214-20.
24. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134; 960-74.
25. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-19.
26. Tsochatzis EA, Gurusamy KS, Ntoutoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a metaanalysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.
27. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
28. Sirli R, Sporea I, Bota S, Jurchis A. Factors influencing reliability of liver stiffness measurements using transient elastography (M-probe) monocentric experience. Eur J Radiol 2013; 82: e313-16.
29. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
30. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
31. StataCorp. Intercooled Stata 6.0 for Windows. College Station, TX: StataCorp; 1998. Available at: http://www.stata.com/
32. Haghdoost AA. Meta-analysis book. 1st ed. Kerman, Iran: Fanus Publication 2011; pp: 138-58. [in Persian]
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
35. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-8.
36. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
37. Lupşor M, Badea R, Ştefănescu H, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19: 53-60.
38. El Bokl MAH, Mabrouk SH, El Karmoty KZ, Bakir ASM, El Aleem AM. Fibroscan as a noninvasive tool in the assessment of the degree of hepatic steatosis in patients with nonalcoholic fatty liver disease. Egyp Liver J 2012; 2: 83-7.
Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71.

40. Mahadeva S, Mahfudz AS, Vijayanathan A, et al. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. J Dig Dis 2013; 14: 604-10.

41. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.

42. Adeabajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18: 323-31.

43. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS ONE 2012; 7: e44930.

44. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-20.

45. Stebbing J, Farouk L, Panos G, et al. A metaanalysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-9.

46. Tschochatzis EA, Gurusamy KS, Ntoulla S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.

47. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40.

48. Kwok R1, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-69.

49. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.

50. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 1288-93.

51. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.

52. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.

53. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.

54. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-103.

55. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-9.

56. Nahon P, Kettaneh A, Tengher-Barna I, et al. Assessment of liver fibrosis using transient elastography in patients with alcholic liver disease. J Hepatol 2008; 49: 1062-8.

57. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-24.

58. Carrión JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-8.

59. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.

60. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-20.